Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Phase: Phase 2"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
PubPharm (1.944)
1
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) : Molecular Analysis for Therapy Choice (MATCH)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer : A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab : Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb : MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma : A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) : MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) : MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) : MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) : MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) : Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[195]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Phase: Phase 2
Medienart
1.944
Aufsätze
1.944
E-Artikel
1.944
E-Ressourcen
Zeitschriftentitel
974
WHO International Clinical Trials Registry Plat...
970
ClinicalTrials.gov
Thema
1.944
610
Phase: Phase 2
1.938
Study Type: Interventional
960
Multiple Myeloma
814
Neoplasms, Plasma Cell
474
Recruitment Status: Not yet recruiting
425
Recruitment Status: Completed
334
Recruitment Status: Authorised-recruitment may ...
293
Medical Condition: Multiple Myeloma
221
Recruitment Status: Recruiting
181
Recruitment Status: Active, not recruiting
142
Lymphoma
135
Recruitment Status: Terminated
84
Leukemia
70
Myelodysplastic Syndromes
66
Medical Condition: Multiple Myeloma MedDRA vers...
63
Neoplasms
56
Recruitment Status: Withdrawn
54
Recruitment Status: Complete: follow-up complete
51
Leukemia, Lymphocytic, Chronic, B-Cell
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
1.234
2020-
688
2010-2019
22
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.936
Englisch
4
Unbestimmt
2
Tschechisch
2
Spanisch
Haven't found what you're looking for?
Wird geladen...